OBJECTIVES: We tested the hypothesis that prostate-specific antigen (PSA) levels would be higher among prostate cancer deaths as compared with controls over time in the 25-year follow-up of the Multiple Risk Factor Intervention Trial of participants ages 35-57 at entry. METHODS: The initial stored serum samples were collected in 1973-1975 and the mean length of follow-up to prostate cancer death was 17 years. RESULTS: There were 63 prostate cancer deaths and 63 controls matched by age, clinical site, and length of follow-up. The mean PSA level for prostate cancer decedents was 2.84 ng/ml as compared with 1.10 ng/ml for controls (P = 0.002 for difference). There were nine men who died from prostate cancer and no controls with PSA levels > 4 ng/ml. Risk of prostate cancer death increased with increasing PSA levels, with increased risk observed even at moderate levels of PSA. Many of those with high PSA levels in 1973-1975 died from prostate cancer many years after the elevated PSA. CONCLUSIONS: PSA levels measured from blood obtained before the introduction of widespread PSA testing were a strong predictor of prostate cancer death over 25 years of follow-up. Studies of prostate cancer etiology and chemoprevention need to focus on middle-aged or younger men with longer follow-up.
OBJECTIVES: We tested the hypothesis that prostate-specific antigen (PSA) levels would be higher among prostate cancer deaths as compared with controls over time in the 25-year follow-up of the Multiple Risk Factor Intervention Trial of participants ages 35-57 at entry. METHODS: The initial stored serum samples were collected in 1973-1975 and the mean length of follow-up to prostate cancer death was 17 years. RESULTS: There were 63 prostate cancer deaths and 63 controls matched by age, clinical site, and length of follow-up. The mean PSA level for prostate cancer decedents was 2.84 ng/ml as compared with 1.10 ng/ml for controls (P = 0.002 for difference). There were nine men who died from prostate cancer and no controls with PSA levels > 4 ng/ml. Risk of prostate cancer death increased with increasing PSA levels, with increased risk observed even at moderate levels of PSA. Many of those with high PSA levels in 1973-1975 died from prostate cancer many years after the elevated PSA. CONCLUSIONS:PSA levels measured from blood obtained before the introduction of widespread PSA testing were a strong predictor of prostate cancer death over 25 years of follow-up. Studies of prostate cancer etiology and chemoprevention need to focus on middle-aged or younger men with longer follow-up.
Authors: Lewis H Kuller; Gregory Grandits; Jerome D Cohen; James D Neaton; Ronald Prineas Journal: Atherosclerosis Date: 2006-10-02 Impact factor: 5.162
Authors: Marvin E Langston; Ratna Pakpahan; Remington L Nevin; Angelo M De Marzo; Debra J Elliott; Charlotte A Gaydos; William B Isaacs; William G Nelson; Lori J Sokoll; Jonathan M Zenilman; Elizabeth A Platz; Siobhan Sutcliffe Journal: Prostate Date: 2018-05-30 Impact factor: 4.104
Authors: Hormuzd A Katki; Amanda Black; Rebecca Landy; Lauren C Houghton; Christine D Berg; Robert L Grubb Journal: Cancer Prev Res (Phila) Date: 2020-01-29
Authors: Mark A Preston; Julie L Batista; Kathryn M Wilson; Sigrid V Carlsson; Travis Gerke; Daniel D Sjoberg; Douglas M Dahl; Howard D Sesso; Adam S Feldman; Peter H Gann; Adam S Kibel; Andrew J Vickers; Lorelei A Mucci Journal: J Clin Oncol Date: 2016-06-13 Impact factor: 44.544
Authors: Andrew J Vickers; David Ulmert; Daniel D Sjoberg; Caroline J Bennette; Thomas Björk; Axel Gerdtsson; Jonas Manjer; Peter M Nilsson; Anders Dahlin; Anders Bjartell; Peter T Scardino; Hans Lilja Journal: BMJ Date: 2013-04-15
Authors: Andrew J Vickers; Daniel D Sjoberg; David Ulmert; Emily Vertosick; Monique J Roobol; Ian Thompson; Eveline A M Heijnsdijk; Harry De Koning; Coral Atoria-Swartz; Peter T Scardino; Hans Lilja Journal: BMC Med Date: 2014-02-11 Impact factor: 8.775